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1. Introduction 
Thyroid hormone (T3 and T4) is secreted from the thyroid gland, and is known to reduce 
the level of serum thyrotropin (thyroid-stimulating hormone, TSH) in the pituitary gland 
(Sarapura et al., 2002; Shupnik et al., 1989) (Fig. 1A). This is a typical example of negative 
feedback between the pituitary and endocrine organs, and is a key component of thyroid 
hormone homeostasis. TSH is one of the peptide hormones generated in the anterior 
pituitary, and is a heterodimer composed of an ┙ chain (┙-glycoprotein subunit, ┙GSU) 
and a ┚ chain (TSH┚) (Shupnik et al., 1989). While ┙GSU is common to follicle stimulating 
hormone (FSH), luteinizing hormone (LH) and chorionic gonadotropin (CG), TSH┚ is 
specific to TSH alone. Although the concentration of serum T4 is much higher than that of 
T3, T4 is converted to T3 by deiodinase (Dio) in the TSH-producing cells (thyrotrophs) of 
the pituitary (Christoffolete et al., 2006), and T3 exhibits biological activity as a thyroid 
hormone (Gereben et al., 2008). T3 inhibits expression of both TSH┚ and ┙GSU at the 
transcriptional level (Shupnik et al., 1989). The magnitude of T3-induced repression of the 
TSH┚ gene is greater than that of ┙GSU. Here, we provide an overview of the molecular 
mechanisms involved in T3-induced negative regulation of the TSH┚ gene and its related 
genes. 
2. Structure of T3 receptors (TRs) 
T3 receptor (TR) belongs to the nuclear hormone receptor (NHR) superfamily, and is a 
ligand-dependent transcription factor (Cheng et al., 2010). TR is encoded by two separate 
alleles; TR┙ and TR┚. Through alternative splicing, the TR┙ gene generates TR┙1 and 
TR┙2, while the TR┚ gene generates TR┚1 and TR┚2 (Fig. 2). While TR┙1, TR┚1 and TR┚2 
have T3-binding capacity, TR┙2 does not bind T3. Hence, TR┙1, TR┚1 and TR┚2 are 
thought to be the functional TRs. TR┚2 is expressed in limited organs including pituitary, 
hypothalamus and retina, while TR┙1 and TR┚1 are ubiquitously expressed (Cheng et al., 
2010). As in the case of other NHRs, TR consists of an N-terminal region (NTD), a central 
DNA binding domain (DBD), a hinge region and a C-terminal ligand binding domain 
(LBD) (Fig. 2).  
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Fig. 1. Negative feedback loop in the hypothalamus-pituitary-thyroid axis and negative 
regulation of TSH┚ and ┙GSU. A. The secretion of TSH (a heterodimer of TSH┚ and ┙GSU 
subunits) in the anterior pituitary and TRH in the hypothalamus is inhibited by thyroid 
hormones (T3 and T4).  ┚, TSH┚ chain.  ┙, ┙GSU chain.  TRH, thyrotropin releasing 
hormone.  Synthesis of TRH in hypothalamus is also negatively regulated by T3.  B. In 
patients resistant to thyroid hormone (RTH), a negative feedback loop is impaired due to a 
defect in T3 receptor (TR) ┚.  This finding provides the evidence for the involvement of TR┚ 
in the negative regulation of the TSH┚ and ┙GSU genes. Because of increased secretion of 
TSH, difuse goiters are often found in the patient with RTH.   
www.intechopen.com
 




Fig. 2. Schematic representations of TR isoforms.  TR consists of an N-terminal region 
(NTD, A/B domain), a central DNA-binding domain (DBD, C domain), a hinge region (D 
domain) and a C-terminal ligand binding domain (LBD, E/F domain). The numbers 
within the box represent the amino acid homology (%). While TR┙1, TR┚1 and TR┚2 have 
T3-binding capacity, TR┙2 does not bind T3. The P and D boxes are required for the 
recognition of half-site sequences (typically, AGGTCA) and the number of spacing 
nucleotides, respectively. The T and A boxes are involved in dimer formation and polarity 
of TR-RXR heterodimers on positive TRE (pTRE). P, Pbox. D, D box. T, Tbox. A, A box. 
RTH, three hot spots where mutations are frequently found in patients with RTH.  AF-2, 
activation function 2.   
3. Mechanism of positive regulation by T3 
TR activates or inhibits the transcription of its target genes in a T3-dependent manner, and 
the molecular mechanism of T3-dependent activation (positive regulation) has been 
elucidated (Cheng et al., 2010) (Fig3A).  Because findings in molecular mechanisms of 
positive regulation by T3 have greatly influenced the studies of negative regulation, it is 
necessary to outline the mechanism of T3-dependent positive regulation (Fig. 3A) before 
describing the negative regulation of the TSH┚ gene (Fig. 3B).  In the positive regulation, TR 
heterodimerizes with retinoid X receptor (RXR) at the T3-responsive element (TRE) of the 
gene, the transcription of which is positively regulated by T3-bound TR (T3/TR) (Cheng et 
al., 2010). In the absence of T3, TR-RXR heterodimers interact with co-repressors, including 
nuclear receptor co-repressor (NCoR) or silencing mediator for retinoid and thyroid 
hormone receptors (SMRT). These co-repressors recruit histone deacetylase (HDAC), which 
represses the transcription of the target genes. This repressive effect by unliganded TR is 
referred to as “silencing” and is thought to play an important role in the clinical symptoms 
in hypothyroidism (Astapova et al., 2008; Astapova et al., 2011). Upon T3 binding, the TR-
RXR heterodimers release NCoR or SMRT and then recruit p160 family cofactors including 
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steroid receptor coactivator-1 (SRC-1). The TR-RXR-p160 complex also recruits an additional 
coactivator, CBP/p300 (Chen et al., 1999; Glass and Rosenfeld, 2000; Huang et al., 2003). 
Both the p160 family and CBP/p300 have intrinsic histone acetyltransferase (HAT) activity 




Fig. 3. Schematic representation of T3-dependent transactivation (positive regulation) (A) 
and transrepression (negative regulation) of the TSH┚ gene (B). A. TR heterodimerizes with 
retinoid X receptor (RXR) on the T3-responsive element (TRE) of the gene, the transcription 
of which is positively regulated by T3-bound TR (T3/TR).  Arrow, half-site sequence 
(typically, AGGTCA). 4xN, random four nucleotides for spacing. B. An nTRE (GGGTCA) 
has been postulated in the region immediately downstream to the transcription start site 
(TSS) of the TSH┚ gene.  In contrast to the mechanism for positive regulation, the molecular 
mechanism of negative regulation has been controversial (see text).   
As shown in Fig. 3A, a typical TRE has a unique configuration designated as direct repeat 
4 (DR4), in which the random four base pairs (spacer) are incorporated into tandem 
repeats of a hexameric half-site (Cheng et al., 2010; Umesono et al., 1991). Both the half-
site sequence (typically AGGTCA) and the number of spacer nucleotides determine the 
specificity for DNA recognition by the TR-RXR heterodimer. Analogous to TR-RXR 
heterodimer binding at DR4, RXR heterodimerizes with vitamin D3 receptor (VDR) on 
direct repeats of half-sites spaced with 3 nucleotides (DR3) and it functions as a 
heterodimer partner for retinoic acid receptor (RAR) on direct repeats spaced with 5 
nucleotides (DR5) (Cheng et al., 2010; Glass and Rosenfeld, 2000). In the studies of 
www.intechopen.com
 
Negative Regulation of the Thyrotropin ┚ Gene by Thyroid Hormone 
 
105 
positive regulation by T3, monkey kidney-derived CV1 cells (Jensen et al., 1964) have 
been often used (Naar et al., 1991; Tillman et al., 1993; Umesono et al., 1991) because they 
possess endogenous RXR but not TR. 
4. Involvement of TR in negative regulation of the TSHβ gene: Syndrome of 
thyroid hormone resistance (RTH)  
Although the molecular mechanism in negative regulation of the TSH gene has been 
disputed (Lazar, 2003; Shupnik, 2000; Weitzel, 2008), it is apparent that TR plays a crucial 
role in it. Syndrome of resistance to thyroid hormone (RTH) is characterized by a reduced 
tissue response to T3 (Fig. 1B). The majority of patients with RTH have mutations in the 
LBD of the TR┚ gene, of which amino acid sequence is shared by TR┚1 and TR┚2 proteins 
(Refetoff et al., 1993) (Fig. 2). These mutant TR┚1s and TR┚2s have defects in their T3-
binding capacity but have intact DBDs capable of recognizing the TRE (Fig. 3A). Thus, they 
bind to the TRE and constitutively interact with NCoR or SMRT, even in the presence of T3, 
resulting in silencing. In the majority of patients with RTH, inheritance is usually autosomal 
dominant, and mutant TR┚ is thought to interfere with T3-induced activation by wild-type 
TR bound to the TRE (dominant negative effect).  Of note, patients with RTH also exhibit 
elevated secretion of TSH (syndrome of inappropriate secretion of TSH, SITSH) (Refetoff et 
al., 1993) (Fig. 1B). This finding provides evidence for the involvement of TR┚ in the 
negative regulation of the TSH┚ and ┙GSU genes.  However, the mechanism downstream to 
TR has been unknown (Lazar, 2003; Shupnik, 2000; Weitzel, 2008).  With regard to the 
mechanism of negative regulation of TSH┚ and ┙GSU, the central question has been whether 
TR directly interacts and recognizes the DNA sequence of the TSH┚ promoter, as identified 
for the TRE in positive regulation. Some theories indicate the direct binding of TR with 
DNA, while others favor models that are independent of a direct binding with DNA.   
5. Direct binding of TR with DNA: Negative TRE (nTRE) hypothesis 
Following the identification of the role of the TRE in the positive regulation of genes (hereafter, 
positive TRE, pTRE), some researchers have postulated a so-called negative TRE (nTRE) in the 
TSH┚ (Fig. 3B) and ┙GSU genes (Chin et al., 1993; Shupnik, 2000; Wondisford et al., 1989). The 
observation that serum TSH levels increase in hypothyroidism led to the idea that unliganded 
TR may be the transcriptional activator for TSH┚ (Fig. 3B, upper panel) and ┙GSU.  If 
unliganded TR is the transcriptional activator on the nTRE of these genes, one may able to 
identify the nTRE as the sequence required for the transcriptional activation by unliganded TR.  
Based on this hypothesis, deletion analysis of the TSH┚ promoter was performed using human 
kidney-derived 293 cells (Wondisford et al., 1989) and it was reported that the transcriptional 
activity of the this promoter was abolished after deletion of a short DNA sequence immediately 
downstream to the transcription start site (TSS) (Wondisford et al., 1989) (Fig. 4). This sequence 
(GGGTCA) has been postulated as the nTRE because it has homology with the consensus 
sequence of a half-site (AGGTCA). The nTRE hypothesis has been regarded as one of the 
principal models to explain the molecular mechanism of negative regulation of the TSH┚ 
gene (Chin et al., 1993; Cohen and Wondisford, 2005), and has been regarded as a potential 
mechanism of T3-dependent negative regulation of other genes (Edwards et al., 1994; Kim et 
al., 2005; Lin et al., 2000; Santos et al., 2006; Wright et al., 1999). However, this raised several 
questions, as discussed below.  
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Fig. 4. Schematic representation of the TSH┚ promoter.  Pit1-US, functional Pit1-binding site. 
GATA-TRE, GATA-responsive element. SR, suppressor region. Pit1-like, the sequence 
similar to Pit1-binding site. TATA. TATA box. An nTRE (GGGTCA) has been postulated 
immediately downstream to the TSS.  
5.1 Does TR heterodimerize with RXR on the nTRE? 
While RXR is the obligate heterodimer partner for TR recognition of the pTRE (Fig. 3A), the 
involvement of RXR with the nTRE has not been determined (Fig. 3B). Although the nTRE 
sequence appears to be a single half-site, there remains the possibility that its flanking 
sequences may function as another half-site (Fig. 3B). However, if TR heterodimerizes with 
RXR on the nTRE, this configuration cannot be discriminated from that present on the pTRE 
(Fig. 3A), which may be functioning as a T3-dependent transcriptional activator but not an 
inhibitor. Previous results of reporter assays examining the effect of RXR overexpression on 
the TSH┚ promoter have been controversial. Cohen et al. (Cohen et al., 1995) and Hallenbeck 
et al. (Hallenbeck et al., 1993) reported that RXR may antagonize inhibition of the TSH┚ gene 
by T3/TR, while Safer et al. (Safer et al., 1997) reported that the requirement for RXR is 
different between TR┚1 and TR┚2. Nagaya et al. (Nagaya and Jameson, 1993) demonstrated 
that mutant TR┚1 (L428R) which is unable to dimerize with RXR failed to mediate T3-
induced inhibition of the ┙GSU promoter, while Takeda et al. (Takeda et al., 1997) reported 
that overexpression of RXR had no effect on this promoter. According to Laflamme et al. 
(Laflamme et al., 2002) RXR enhances the negative regulation of the TSH┚ gene by T3, and 
this effect is mediated by the RXR-LBD and but not the DBD, suggesting that RXR may act 
as a cofactor.  
It was reported that the ligand for RXR (rexinoids) has inhibitory effect on TSH┚ expression 
(Sherman et al., 1999). However, subsequent analysis revealed that the signaling pathway is 
mediated via a nt. -200/-149 region of the mouse TSH┚ gene, which is different from the 
reported nTRE (GGGTCA at nt. +1/+6) (Sharma et al., 2006). While T3 inhibits the synthesis 
of thyrotropin releasing hormone (TRH) in hypothalamus (Fig 1A) and a nTRE is postulated 
in this gene (Hollenberg et al., 1995), rexinoids has no effect on its production (Sherman et 
al., 1999). It was reported that the transcription of the TSH┚ gene is repressed in the CV1 
cells treated with retinoic acid (RA) (Breen et al., 1995); however, its precise mechanism is 
unknown.  Although all three RXRs, ┙, ┚ and ┛, are expressed in TSHoma cells, TtT97 
(Sharma et al., 2006), double immunostaining studies of the hypothyroid rat pituitary using 
an antibodies against pituitary hormones and RXR suggest that RXR┛ is predominantly 
expressed in thyrotrophs (Sugawara et al., 1995). Barros et al. (Barros et al., 1998) reported 
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that no alteration in the serum level of TSH, T3 or T4 was observed in RXR┙ (-/+) mice or 
RXR┛ (-/-) mice. The authors suggested that ablation of RXRs has little effect on the negative 
regulation of the TSH┚ gene. Currently, there are few rationales to confirm the recognition 
of the nTRE by TR-RXR heterodimers.  
5.2 Does TR bind to the nTRE as a monomer? 
Gel shift assays indicate that TR monomers bind with the nTRE and that this interaction is 
abolished by RXR (Cohen et al., 1995). However, the hypothesis that TR binds with the 
nTRE as a monomer (Fig. 3B) also raises other questions which are difficult to answer. First, 
for the direct recognition of DNA sequence by DNA-binding transcription factors including 
NHRs, formation of a homo- or heterodimer is usually required. As expected, gel shift 
assays revealed that TR-monomer binding with single half-sites (i.e. nTRE) is much weaker 
than that of TR-RXR heterodimer binding to DR4 (Cohen et al., 1995). It should be noted that 
TSH synthesis in severe hypothyroidism is dramatically high (Fisher et al., 2000). Given that 
unliganded TR may maintain the basal activity of the TSH┚ promoter in hypothyroidism, it 
is difficult to imagine that such a weak binding of TR monomer with the nTRE can achieve 
this high level of transcriptional activity. Second, there is ligand/NHR selectivity, i.e., the 
negative regulation of the TSH┚ gene is clinically specific to T3 and partially estrogen (E2), 
but not other NHR ligands (Cohen and Wondisford, 2005). While, in positive regulation, the 
number of spacing nucleotides between half-sites is a critical factor in determining receptor 
specificity, it is unknown as to how TR selectively recognizes the nTRE DNA sequence in 
the TSH┚ gene. Finally, it is not easy to explain why TR monomers on a single half-site can 
exhibit reverse functions, i.e. recruitment of co-activators in the absence of T3 and 
association with co-repressors in the presence of T3 (Fig. 3B).  We proposed previously a 
model where TR is able to bind with reported nTRE only in the presence of T3 (Sasaki et al., 
1999).  Although the nTRE in the TSH┚ gene was originally defined on the basis of the 
experiments with non-pituitary 293 cells (Wondisford et al., 1989), we and other 
investigators suggested the possibility that an unknown thyrotroph-specific factor may 
switch T3/TR on the nTRE from a transcriptional activator to an inhibitor (Sasaki et al., 
1999; Shupnik, 2000; Wondisford et al., 1993). However, its existence has not been confirmed 
because of the limited number of cultured thyrotroph cell lines available (Ooi et al., 2004; 
Sarapura et al., 2002).   
6. Models that do not postulate direct DNA binding of TR 
The following hypotheses proposed models for T3-induced negative regulation without the 
involvement of direct DNA binding of TR.  
6.1 NCoR or SMRT 
There are many studies with regard to the involvement of NCoR or SMRT in the negative 
regulation by T3.  It was reported that co-expression of NCoR and SMRT may enhance basal 
stimulation of the TSH┚, ┙GSU and prepro-TRH promoters in a TR-dependent manner 
(Tagami et al., 1997).  With regard to the T3-induced negative regulation of the Rous 
sarcoma virus-derived 5’ truncated terminal repeat (RSV-LTR) (Berghagen et al., 2002) and 
the rat CD44 gene (Kim et al., 2005), it was reported that NCoR and SMRT may function as 
transcriptional co-activators in the transcriptional regulation of these genes. According to 
www.intechopen.com
  
Contemporary Aspects of Endocrinology 
 
108 
Tagami et al. (Tagami et al., 1999), unliganded TR in solution may squelch NCoR or SMRT 
from the transcription factor on the target promoter. Upon T3 binding, TR may release these 
co-repressors, resulting in their association with the DNA-binding transcription factor, 
which maintains the basal activity of the promoter of the target gene. However, this notion 
was tempered by following questions. First, the mechanism involved in the association of 
NCoR or SMRT with the target promoters is unknown. Second, it was undetermined 
whether the majority of NCoR and SMRT are sequestered by the relatively limited amount 
of intracellular TR (5000 to 10000 molecule/cell) (Oppenheimer et al., 1974). Third, NCoR 
and SMRT also interact with unliganded RAR and peroxisome proliferator-activated 
receptors (PPARs) (Nofsinger et al., 2008; Suzuki et al., 2010). It is unlikely that these NHRs 
also inhibit TSH┚ or ┙GSU expression in the presence of cognate ligands. Finally, it was 
reported that the negative regulation by T3 is mediated by the mutant TR┚, AHT, of which 
interaction with co-repressors is impaired (Nakano et al., 2004).  Using an experimental 
model similar to the mammalian two-hybrid assay, Wulf et al. (Wulf et al., 2008) also 
demonstrated that negative regulation by T3/TR is possible via the interaction of TR with a 
co-repressor. However, their experimental setting was completely artificial.   
Amino acid sequence of TR2-NTD is unique and has low homology with that of TR1 or 
TR┙1 (Fig. 2).  The N-terminal domain of TR┚2 is known to neutralize the silencing activity 
of co-repressors in the context of TR-RXR heterodimers on the pTRE (Hollenberg et al., 1996; 
Yang et al., 1999), and the NTD of TR┚2 may have some role in the negative regulation of 
the prepro-TRH gene (Guissouma et al., 2002).  However, the physiological relevance in the 
negative regulation of TSH┚ gene is unknown.  Of note, in vitro experiments showed that 
not only TR┚2 but also TR1 and TR1 can inhibit the transcription of the TSH┚ gene in a T3 
dependent manner (Nakano et al., 2004).  The findings in TR┚/TR┙-double knockout mice 
(Gothe et al., 1999) indicates that TR┙1 is partially involved in the negative regulation of 
TSH┚ gene although its expression level is less than that of TR┚2 (see below).   
The amino acid sequence required for the interaction of NCoR and SMRT with unliganded 
TR has been identified. Based on this information, mice harboring mutant SMRT 
(SMRTmRID) (Nofsinger et al., 2008) or mutant NCoR (NCoRΔID) (Astapova et al., 2011), 
which results in defective interaction with unliganded TR, were established. Importantly, 
the negative regulation of the TSH┚ gene by T3 was not impaired in knock-in mice with 
SMRTmRID or NCoRΔID, although the latter exhibited a reduced amount of TR protein in 
the pituitary gland and reduced sensitivity for TSH by the thyroid gland. Likewise, TRH 
expression in the hypothalamus was not affected in NCoRΔID-knock-in mice (Astapova et 
al., 2011). This is supported by an in vivo study, which showed that the overexpression of 
these co-repressors is incompatible with physiological regulation of TRH (Becker et al., 
2001). As in the cases of the TSH┚ and ┙GSU genes, mRNA expression of the myosin heavy 
chain ┚ subunit (MHC┚) gene in the heart is also repressed by T3/TR (Gupta, 2007). In 
NCoRΔID mice, T3-induced inhibition of MHC┚ is maintained (Astapova et al., 2011).  
Moreover, Astapova et al, (Astapova et al., 2008) established a liver-specific NCoRΔID 
knock-in mouse. According to them, of 326 genes that are negatively regulated by T3 in the 
liver, only 3 genes were repressed in hypothyroid conditions, suggesting little effect of 
NCoR on the majority of the negatively regulated T3-target genes. While SMRTmRID- or 
NCoRΔID-knock-in mice survive, the global deletion of both the NCoR and SMRT genes are 
embryonic lethal (Jepsen et al., 2007). These findings suggest that NCoR and SMRT have 
important roles other than interaction with liganded NHRs. For example, they interact with 
www.intechopen.com
 
Negative Regulation of the Thyrotropin ┚ Gene by Thyroid Hormone 
 
109 
p53, Myc, MyoD Ptx1 and Foxo1 (Nofsinger et al., 2008). Thus, it is unlikely that T3-binding 
with TR affects the transcriptional regulation of all of the genes regulated by NCoR or SMRT 
in vivo.  
6.2 CBP/p300 and p160 family 
cAMP-response-element-binding protein-binding protein (CBP)/p300 is required for 
transactivation by multiple DNA-binding transcription factors including NFkB and AP-1, 
and functions as a coactivator for liganded NHRs (Kamei et al., 1996). As a model for the 
ligand-dependent inhibition by NHRs, it was proposed that liganded NHRs may attenuate 
the transactivation by DNA-binding transcription factors via interference of CBP/p300 
function (Kamei et al., 1996). However, subsequent studies reported that inhibition by 
liganded NHR is not rescued by overexpression of these co-activators (De Bosscher et al., 
1997; De Bosscher et al., 2001; Wu et al., 2004). It was also suggested that the CBP/p300-
interacting surface on the NHR-LBD may be different from that required for T3-dependent 
inhibition (Saatcioglu et al., 1997; Valentine et al., 2000).  
Although inappropriate overexpression of TSH is reported in SRC1-deficient mice (Takeuchi 
et al., 2002), it is difficult to determine what adaptive processes have occurred during 
pituitary development in SRC-1(-/-) mice since ablation of the SRC-1 gene also affects the 
expression of other p160 family members and TRs (Sadow et al., 2003; Xu et al., 1998).  While 
p160 proteins are known to interact with multiple NHRs other than TR in a ligand-
dependent manner, inhibition of the TSH┚ gene or the ┙GSU gene is specific to T3, and 
partially estrogen (Cohen and Wondisford, 2005). In some patients with RTH, there are no 
mutations of the TR┚ or TR┙ gene (non-TR RTH) (Refetoff and Dumitrescu, 2007; Refetoff et 
al., 1993). Although defects in cofactors that may mediate the negative regulation of the 
TSH┚ gene have been postulated in these cases, linkage analyses with polymorphic markers 
showed that the involvement of SRC-1, NCoR, SMRT or RXR┛ is unlikely (Reutrakul et al., 
2000).  
6.3 Protein-protein interaction of TR with DNA-binding transcription factors: Tethering 
model 
In vitro binding assays, including gel shift assays, are limited in that the amount of TR 
and/or RXR used may not always reflect the in vivo situation. To overcome this problem, 
Shibusawa et al. (Shibusawa et al., 2003a; Shibusawa et al., 2003b) established mice in which 
TR┚ is unable to bind DNA due to a mutation in its DBD. They reported that the negative 
regulation of the TSH┚ gene is relieved in these mice. One may assume that this result 
provides evidence for the direct binding of TR┚ with the nTRE because, in positive 
regulation, the pTRE is recognized by the TR-DBD. However, the function of the DBD of 
NHR is not limited to DNA recognition. It is known that the DBD also interacts with other 
DNA-binding transcription factors including NFkB (De Bosscher et al., 2003; Kalaitzidis and 
Gilmore, 2005; Kalkhoven et al., 1996; Ray and Prefontaine, 1994; Scheinman et al., 1995; 
Stein and Yang, 1995; Tao et al., 2001; Wissink et al., 1997), AP-1 (typically Jun/Fos 
heterodimers) (De Bosscher et al., 2001; Heck et al., 1994; Lopez et al., 1993; Schule et al., 
1990; Webb et al., 1995), Nur77 (Martens et al., 2005) and GATA family transcription factors 
(Clabby et al., 2003; Matsushita et al., 2007), resulting in their inhibition by NHRs in a 
ligand-dependent fashion.  
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This kind of ligand-induced repression via protein–protein interactions is referred to as the 
"tethering mechanism" (De Bosscher et al., 2003; Herrlich, 2001; Nissen and Yamamoto, 2000; 
Pfahl, 1993). Thus, while mutation of the TR┚ DBD abrogates the negative regulation of the 
TSH┚ gene by T3, it does not always imply a direct interaction of the TR with DNA. Of note, 
there are ligand/receptor specificities in the repression by liganded NHRs via the tethering 
mechanism (Caldenhoven et al., 1995; Liden et al., 1997; Matsushita et al., 2007). Moreover, 
dimer formation is not always required for ligand-dependent inhibition via the tethering 
mechanism. A mutant glucocorticoid receptor (GR), A458T, is known to have a defect in 
dimer formation and therefore in glucocorticoid-responsive element-dependent 
transactivation. It was reported that functions that require cross-talk with other 
transcription factors, such as transrepression of the AP-1-driven genes, remain intact in this 
mutant GR (Herrlich, 2001; Reichardt et al., 1998).  This raises again the question whether 
heterodimer formation of TR with RXR is necessary for the negative regulation of the TSH┚ 
gene by T3.   
7. Other possible mechanisms 
Although T3 treatment is known to reduce the stability of TSH┚ mRNA (Krane et al., 1991), 
the role of TR has not been clarified, and the involvement of similar mechanisms in the 
regulation of the ┙GSU mRNA have not been reported (Staton et al., 2000). A mechanism 
operating via anti-sense RNA was proposed to be involved in negative regulation of the 
MHC┚ gene by T3 (Danzi and Klein, 2005; Haddad et al., 2003). In rat chromosome 15, the 
MHC┚ gene is located upstream to the MHC gene, which has a classic pTRE. It was 
reported that, in a T3-dependent manner, TR-RXR heterodimers at pTRE of the MHC 
promoter may activate not only MHC transcription but also synthesis of anti-sense RNA 
against the MHC┚ gene, resulting in the antagonism of MHC┚ expression. However, this 
kind of mechanism has not been reported in other negatively regulated genes including the 
TSH┚ or the ┙GSU genes.  
8. Artificial negative regulation by T3/TR  
There have been at least two technical problems that have hindered the elucidation of the 
mechanism of negative regulation by T3/T.  
8.1 pUC/pBR322-derived AP-1 site 
As shown above, liganded NHRs, including T3/TR and liganded GR, inhibit the 
transcriptional activity of AP-1 via the tethering mechanism. Unexpectedly, a functional AP-
1 site was identified in nt. 1/138 of pUC-derived plasmids and its activity is repressed by 
T3/TR (Lopez et al., 1993). More than 2000 plasmid constructs bearing the sequence 
identical to nt. 1/138 in the pUC18/19 vector were detected in the BLAST database. 
Interestingly, our computer search revealed that this site is also included in the pBR322 
vector (Yanisch-Perron et al., 1985). In early molecular biology studies, both vectors were 
often utilized in “home-made plasmids”. Unfortunately, this AP-1 site was contaminated in 
some of the plasmids used for the analysis of TSH┚ negative regulation by T3 (Hallenbeck et 
al., 1993; Wondisford et al., 1989).  
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8.2 Firefly luciferase gene 
The firefly luciferase assay has been utilized in a variety of analyses of transcriptional 
regulation, including negative regulation of the TSH┚ and the ┙GSU genes due to its 
advantage over the CAT assay (Misawa et al.). However, at least in CV1 cells (Tillman et al., 
1993), JEG3 cells (Maia et al., 1996) and Hepa1-6 mouse hepatoma cells (Chan et al., 2008), 
firefly luciferase cDNA has been reported to function as a transcriptional regulatory 
sequence that mediates artificial negative regulation by T3/TR. The length of firefly 
luciferase cDNA (1653 bp) is much longer than that of the CAT gene (657 bp). A computer 
search predicts more than 250 potential sites for DNA-binding transcription factors in firefly 
luciferase cDNA (Liu and Brent, 2008). Misawa et al. (Misawa et al.) recently found that 
firefly luciferase cDNA behaves as a transcriptional enhancer that can be stimulated by the 
protein kinase C activator, phorbol 12-O-tetradecanoate-13-acetate (TPA), and that this 
activity is inhibited by T3/TR in CV1 and JEG3 cells. The cDNA sequences of modified 
firefly luciferase (luc+) (Annicotte et al., 2001; Paguio et al., 2005) and conventional Renilla 
luciferase (RL) (Ho and Strauss, 2004; Osborne and Tonissen, 2002; Zhuang et al., 2001) also 
harbor numerous short sequences that can be recognized by a variety of transcription 
factors. Modified luciferase genes, including hRluc (Zhuang et al., 2001) and Luc2 (Paguio et 
al., 2005), may be more reliable than firefly luciferase (Misawa et al.), presumably because 
the majority of predicted transcription factor binding sites were mutated.  
8.3 Problems with artificial negative regulation in the identification of the nTREs by 
reporter assays 
When a strong promoter is fused to firefly luciferase cDNA, the activity of this DNA sequence 
as a transcriptional regulatory element can be negligible. Nonetheless, one should remember 
that sequential deletion or mutation of the promoter sequence often reduces its transcriptional 
activity. Once the activity of the promoter becomes lower than that of the activity via the firefly 
luciferase gene, the overall activity of the reporter gene may represent that of the firefly 
luciferase cDNA, which can be artificially inhibited by T3/TR.  For example, a deletion 
analysis to identify a nTRE in the ┙GSU gene was also carried out using the firefly luciferase 
reporter system in JEG3 cells (Madison et al., 1993).  However, nTRE was not identified 
because T3-induced negative regulation was detected even a promoter that only has a TATA 
box and a TSS. There is the possibility that sequential deletion of DNA might reduce the 
transcription activity of the ┙GSU promoter, thereby permitting the firefly luciferase cDNA to 
function as a transcriptional regulatory element, resulting in artificial suppression by T3/TR.  
Using the luciferase reporter gene, it was previously proposed that the nTRE of the TSH┚ gene 
may have a direct repeat configuration without spacing nucleotides (DR0) (Naar et al., 1991). 
The authors reported that a reduction in spacing nucleotide number may convert DR4 from a 
pTRE to a nTRE. Unexpectedly, this was not reproduced by the CAT-based reporter system 
(private communication from Dr. Kazuhiko Umesono). According to Tillman et al. (Tillman et 
al., 1993), deletion of spacing nucleotides might destroy the T3-dependent activation and 
allowed artificial repression by T3/TR via firefly luciferase cDNA.  
Whereas firefly luciferase assay has broad linearity, careful interpretation and appropriate 
control are necessary in particular when the promoter activity before T3 addition is reduced 
in the course of deletion or mutation analysis (Misawa et al.).  Although several nTREs in 
different genes have been suggested in the vicinity of TSSs, few of these reports excluded 
the possibility of T3-mediated artificial negative regulation by a reporter plasmid backbone.  
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9. TR2 is the main mediator for the negative regulation of the TSH gene by 
T3  
There is one family with RTH in which the TR┚ allele was globally deleted (Takeda et al., 
1992). Elevated synthesis of TSH, i.e. SITSH, was found in a homozygote in this family, 
presumably due to the defect in TR signaling in the thyrotrophs. Likewise, mice deficient for 
the TR┚ gene exhibit increased expression of TSH┚ and ┙GSU in thyrotrophs (Forrest et al., 
1996). These findings imply the involvement of TR┚ in the negative regulation of these 
genes. Moreover, Abel et al. (Abel et al., 1999) reported that TR┚2-null mice develop a 
similar degree of central resistance to T3 similarly to TR┚-null mice, suggesting that, among 
TR┚1, TR┚2 and TR┙1, TR┚2 is the main mediator for the inhibition of the TSH┚ gene. This 
notion is compatible with our findings that the expression of TR┚2 is much higher than 
TR┙1 or TR┚1 (Nakano et al., 2004) in the thyrotroph cell line, T┙T1 (Yusta et al., 1998). The 
fact that no resistance to T3 is observed in mice deficient for the TR┙ gene (Fraichard et al., 
1997; Wikstrom et al., 1998) indicates that TR┙1 in thyrotrophs has a limited role in the 
negative feedback of the TSH┚ gene by T3. It should be noted, however, that serum TSH 
levels in TR┚/TR┙-double knockout mice (Gothe et al., 1999) is higher than TR┚-null mice 
(Forrest et al., 1996). Hence, the negative regulation of the TSH┚ gene is partially mediated 
by TR┙1 in vivo.   
10. What is the mechanism that maintains the basal transcriptional activity of 
the TSHβ gene before T3 addition? 
It is apparent that the negative regulation of the TSH┚ gene by T3/TR can be observed only 
when its promoter is activated prior to T3 addition.  However, previous studies have paid 
little attention to the mechanism of activation because some of the hypotheses mentioned 
above regard the basal transcriptional activity of the TSH┚ gene to be maintained by 
unliganded TR.  In addition, due to the limitation of the cell lines that recapitulate the 
thyrotroph phenotype (Ooi et al., 2004; Sarapura et al., 2002), the nTRE of the TSH┚ gene has 
been studied using either kidney-derived 293 cells (Wondisford et al., 1989), COS cells (Carr 
et al., 1992) or somatotroph-derived GH3 cells (Sasaki et al., 1999).  Of note, even in the 
presence of overexpressed TR, the magnitude of the basal transcriptional activity of the 
TSH┚ gene prior to T3 addition is extremely low in these cell lines (Sasaki et al., 1999; 
Wondisford et al., 1989), and is almost negligible compared with that observed in the 
presence of the thyrotroph-specific transcription factors, Pit1 and GATA2 (Nakano et al., 
2004) (see below).  
11. Unliganded TR per se is not a transcriptional activator for the TSHβ gene 
Because negative regulation has been regarded as the mirror image of the positive 
regulation, unliganded TR was thought to be a transcriptional activator (Wondisford et al., 
1989).  If this were the case, TSH┚ and ┙GSU expression would be reduced in mice lacking 
the TR gene irrespective of serum T3 and T4 levels. However, as described above, their 
expression was not reduced but rather was increased in mice deficient for the TR┚ gene 
(Abel et al., 1999; Forrest et al., 1996; Weiss et al., 1997) or both TR┙ and TR┚ genes (Gothe et 
al., 1999).  In the family with RTH, in which the TR┚ allele is globally deleted (Takeda et al., 
1992), elevation of serum TSH was also found in the homozygotes of this family. This again 
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suggests that unliganded TR┚ is not necessary for the activity of the TSH┚ promoter in 
human and that the TSH┚ gene is activated by factors other than unliganded TR.  
12. GATA2 and Pit1 maintain basal TSHβ expression in thyrotrophs 
It is known that a pituitary-specific transcription factor, Pit1 (Fig 5A), plays a critical role in 
TSH┚ expression since its mutation causes combined pituitary hormone deficiency (CPHD), 
where the syntheses of TSH┚, prolactin and growth hormone are crippled or abolished 




Fig. 5. Schematic representations of Pit1 (A) and GATA1, 2 and 3 (B).  A. CBP, amino acid 
sequence interacting with CBP. POUS, POU specific domain. POUH. POU homeodomain. 
GATA, amino acid sequence interacting with GATA2. B. Structure of GATA1, 2, 3, GATA2-
NZ and GATA2-ZC (see text). The numbers within the box represent the amino acid 
homology (%).  
Promoter analysis of the TSH┚ gene in TSHoma cells, TtT97, revealed that nt. -269 from the 
TSS is sufficient for thyrotroph-specific expression of this gene (Wood et al., 1990). As 
shown in Fig. 4, a functional Pit1-binding site is included in this region (Haugen et al., 1993) 
and was designated as Pit1-US (Kashiwabara et al., 2009). Interestingly, comparison of the 
pattern of DNA foot printing using nuclear extracts from TtT97 cells and that from GH3 
cells revealed that this promoter region also has binding sites for the transcription factor, 
GATA2 (Fig 4 and 5B) (Gordon et al., 1997), which was originally identified to be involved 
in the gene regulation of a hematopoietic cell lineage (Shimizu and Yamamoto, 2005). 
Indeed, there are two GATA-responsive elements (GATA-REs) immediately downstream of 
the Pit1-US (Gordon et al., 1997). Subsequent analysis with various transgenic mice revealed 
that co-expression of Pit1 and GATA2 is crucial for the differentiation of thyrotrophs (Dasen 
et al., 1999).  
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13. GATA2, not Pit1, is the true activator that drives the promoter activity of 
TSHβ 
Kashiwabara et al. (Kashiwabara et al., 2009) reported that the co-operation of Pit1 with 
GATA2 is strictly determined by the number of nucleotides between the Pit1-US and 
GATA-REs (Fig 4), and suggested the possibility that a configuration of the Pit1-US and 






Fig. 6. Molecular mechanism of the transcriptional regulation of the TSH┚ gene. A 
configuration of the Pit1-US and GATA-REs may be critical for the recruitment of 
CBP/p300.  T3/TR represses the GATA2-dependent activation of the TSH┚ promoter via a 
tethering mechanism. Pit1 binds with the Pit1-like element in SR and competes with SR 
binding protein (SRBP), resulting in protection of GATA2 functionality from inhibition by 
SR (de-repression). TRH-R, TRH receptor,  FOG2, friend of GATA 2.   
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The authors also noticed that a 30bp region downstream from the GATA-REs is highly 
conserved among rat, mice and humans, and includes a sequence similar to the Pit1-binding 
site (Pit1-like element, Fig. 4). This sequence was designated the suppressor region (SR) 
because its deletion increased the transactivation by GATA2 and Pit1. Interestingly, deletion 
of the SR enabled GATA2 to transactivate the TSH┚ gene without Pit1. Detailed analysis 
revealed that Pit1 binds with the Pit1-like element in the SR (Fig. 4) and competes with 
binding of SR binding protein (SRBP), resulting in protection of the GATA2 function from 
inhibition by SRBP (Fig 6). Thus, cooperation of Pit1 with GATA2 is not synergistic, but Pit1 
protects  GATA2 from inhibition by SR (de-repression). These findings not only provide an 
insight as to why TSH┚ expression is restricted in thyrotrophs where Pit1 and GATA2 co-
exist, but also imply that the true activator that drives the TSH┚ promoter activity is GATA2 
but not Pit1 (Kashiwabara et al., 2009).  
14. Negative regulation of the TSHβ gene is not the mirror image of positive 
regulation 
Gordon et al. (Gordon et al., 1997) reported that the TSH┚ gene can be activated by Pit1 
and GATA2 in CV1 cells. Because CV1 cells are kidney derived and has been utilized in 
the studies of positive regulation by T3/TR (Naar et al., 1991; Tillman et al., 1993; 
Umesono et al., 1991), Nakano et al. (Nakano et al., 2004) tested whether negative 
regulation of TSH┚ by T3 may be simulated when TR is co-expressed with Pit1 and 
GATA2 in this cell line. They employed the CAT-based reporter gene, TSH┚-CAT (Sasaki 
et al., 1999), in which the pUC/pBR322-derived AP-1 element (Lopez et al., 1993) was 
deleted. Using this experimental system, Nakano et al. (Nakano et al., 2004) found the 
following results. First, T3-induced inhibition of the TSH┚ gene was readily observed in 
CV1 cells transfected with Pit1, GATA2 and TR┚2. This implies that T3-induced negative 
regulation of the TSH┚ gene does not require so-called thyrotroph specific factors except 
for Pit1, GATA2 and TR. Second, T3-induced inhibition was also detected with all three 
functional TRs, TR┚1, TR┚2 and TR┙1, with TR┚2 exhibiting the most potent T3-
dependent inhibition among them. This observation again supports the notion that TR┚2 
is the principal TR that mediates negative regulation of the TSH┚ gene (Abel et al., 1999). 
Third, without Pit1 or GATA2, unliganded TR did not transactivate the TSH┚ promoter at 
all. This implies that unliganded TR alone is not the transcriptional activator. This notion 
is in line with the results of data from TR┚-knockout mice (Forrest et al., 1996) and 
TR┚/TR┙-double knockout mice (Gothe et al., 1999). Therefore, in negative regulation of 
the TSH┚ gene, T3/TR is a transcriptional repressor, but unliganded TR per se is not an 
activator. This is in contrast with positive regulation (Fig. 3A), where the T3-target genes 
are activated by T3/TR while it is repressed by unliganded TR (silencing). These findings 
run counter to the hypothesis that the negative regulation of this gene may be a mirror 
image of its positive regulation (Wondisford et al., 1989).  
15. T3/TR represses GATA2-dependent activation of the TSHβ promoter via 
the tethering mechanism 
The putative nTRE was defined by analysis of the TSH promoter in the absence of T3 
(Wondisford et al., 1989).  Because this was based on the hypothesis that unliganded TR 
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may be a transcriptional activator, Matsushita et al. (Matsushita et al., 2007) re-evaluated the 
function of nTRE by deletion analysis of this promoter (Fig. 4) in the presence of Pit1, 
GATA2 and TR.  Unexpectedly, we found that repression of the TSH┚ promoter by 
T3/TR┚2 was maintained after the nTRE is completely deleted or mutated. Thus, the 
reported nTRE (Fig. 4) is dispensable for T3/TR-dependent inhibition. Moreover, repression 
by T3/TR was also observed even in a deletion construct that has only Pit1-US and two 
GATA-REs. These findings suggest that direct DNA binding of TR is unnecessary and that 
the mechanism for T3-dependent inhibition may be mediated by the crosstalk of T3/TR 
with Pit1 or GATA2 (Matsushita et al., 2007).  
As mentioned above, the true activator that drives the TSH promoter is GATA2 but not 
Pit1 (Kashiwabara et al., 2009) and the deletion of SR enables GATA2 to transactivate the 
TSH┚ promoter without Pit1. Using the reporter gene lacking for SR, Matsushita et al. 
(Matsushita et al., 2007) found that T3/TR┚2 inhibits the transactivation by GATA2 alone. 
Thus, GATA2 is thought to be the target of inhibition by T3/TR (Fig. 6).  This notion is 
supported by the observation that T3/TR┚2 inhibits GATA2-induced activation of the ┙GSU 
promoter and the endothelin-1 (ET-1) promoter, both of which are known to bear a 
functional GATA-RE (Jorgensen et al., 2004; Steger et al., 1994; Dorfman et al., 1992). In 
addition, T3/TR inhibited the CD34 gene-derived GATA-RE fused to a heterologous 
thymidine kinase promoter (Matsushita et al., 2007). Co-immunoprecipitation experiments 
and GST-pull down assays demonstrated that the DBD of TR┚2 interacts with the Zn finger 
domain of GATA2 in vivo in a T3-independent manner. Thus, the TR-DBD is involved in 
protein-protein interactions with GATA2 but not in direct binding of DNA (Matsushita et 
al., 2007). These results indicate that negative regulation of the TSH┚ gene is mediated by 
tethering of T3/TR by GATA2 (Fig. 6).    
16. Ligand/receptor specificity in negative regulation of the TSHβ gene  
As discussed above, ligand/receptor specificity has been reported in ligand-dependent 
inhibition via the tethering mechanism (Caldenhoven et al., 1995; Liden et al., 1997). 
Matsushita et al. (Matsushita et al., 2007) found that GATA2-induced activity of the TSH┚ 
promoter was specifically inhibited by T3/TR but not by RA/RAR or vitamins D3 
(VD3)/VDR. This may reflect ligand selectivity in vivo in negative regulation of the TSH┚ 
gene (Cohen and Wondisford, 2005).  Of note, it is known that estrogen (E2) inhibits 
expression of the TSH┚ gene (Cohen and Wondisford, 2005) at the transcriptional level, 
although its magnitude is smaller than that by T3. E2 is also known to reduce expression of 
the ┙GSU gene (Chaidarun et al., 1994; Shupnik et al., 1988), the promoter of which has a 
functional GATA-RE (Jorgensen et al., 2004; Steger et al., 1994). In agreement, the serum 
level of TSH in women has a tendency to elevate after the menopause (Nagayama et al., 
2008). To explore the molecular mechanism underlying inhibition by E2, Nagayama et al. 
(Nagayama et al., 2008) tested the effect of E2-bound ER┙ (E2/ER┙) using CV1 cells 
cotransfected with Pit1 and GATA2, and found that E2/ER┙ significantly inhibits activity of 
the TSH┚ promoter. As predicted, the magnitude of inhibition by E2/ER┙ was 
approximately half of that by T3/TR┚2. They also found that E2/ER┙ directly interacts with 
GATA2, as shown for GATA1. Testosterone was reported to have the effect similar to 
estrogen, presumably due to the conversion of testosterone to estrogen (Ahlquist et al., 
www.intechopen.com
 
Negative Regulation of the Thyrotropin ┚ Gene by Thyroid Hormone 
 
117 
1987). This may explain why elevation of serum TSH level is also found in aged men (Surks 
and Hollowell, 2007).  
17. The role of GATA2 and TR in TRH signaling in thyrotrophs 
TRH is processed from prepro-TRH and secreted from the hypothalamus (Fig. 1A). TRH 
signaling not only stimulates TSH secretion but also enhances expression of TSH┚ and ┙GSU 
(Franklyn et al., 1986; Shupnik et al., 1986). To clarify the role of TRH-induced 
transactivation and T3/TR mediated inhibition in the hypothalamic-pituitary-thyroid (H-T-
P) axis, various in vivo studies, including genetic ablation of these genes, have been 
performed (Forrest et al., 1996; Friedrichsen et al., 2004; Gothe et al., 1999; Mittag et al., 2009; 
Nikrodhanond et al., 2006; Shibusawa et al., 2000). Although the in vivo evidence observed 
in these experiments is definitely important, the experimental system using cultured cells 
has the advantage that the effect of individual hormone can be analyzed in detail without 
influence by a negative feedback loop.  
17.1 TRH signaling-promoted TSHβ expression is mediated by GATA2 
Although serum TSH levels are reduced in patient with CPHD who have mutations in the 
Pit1 gene (Cohen and Radovick, 2002), the involvement of Pit1 downstream of TRH 
signaling has been controversial (Ohba et al., 2011; Steinfelder et al., 1992a; Steinfelder et al., 
1992b). Unfortunately, previous analyses have been performed without consideration of 
GATA2. Interestingly, the increase in TSH┚ expression in hypothyroidism was impaired in 
mice with pituitary-specific ablation of the GATA2 gene (Charles et al., 2006). Because TRH 
synthesis in the hypothalamus is expected to increased in hypothyroidism (Fig. 1A) (Abel et 
al., 2001; Kakucska et al., 1992), this finding suggested the involvement of GATA2 in the 
TRH signaling pathway.  
Using CV1, GH3 and T┙T1 cells, Ohba et al. (Ohba et al., 2011) recently reported that TRH 
signaling potentiates GATA2/Pit1-induced transcriptional activity of the TSH┚ gene. 
Additionally, experiments with a TSH┚ promoter that lacks SR revealed that GATA2 but not 
Pit1 is the target of TRH signaling (Fig. 6). Similar results were obtained with GATA2-
induced activation of the ┙GSU and ET-1 promoters. It is known that the signal from TRH 
receptor activates protein kinase C (PKC) (Gershengorn and Osman, 1996; Sun et al., 2003). 
The PKC pathway is also known to enhance DNA binding of GATA2 with GATA-RE in the 
┙GSU (Fowkes et al., 2002) and the V-CAM1 promoters (Minami et al., 2003). Gel shift assays 
also suggested that DNA binding of GATA2 with the TSH┚ promoter is facilitated by the 
TRH/PKC pathway (Ohba et al., 2011).  Thus, GATA-REs seem to be the point of 
convergence for both activation and inhibition signals controlling TSH transcription.  
Although it has been postulated that TRH signaling in transactivation of the TSH┚ gene may 
be mediated by unliganded TR on nTRE (Wondisford et al., 1993), Ohba et al. (Ohba et al., 
2011) showed that unliganded TR without Pit1 or GATA2 failed to mediate the stimulating 
effect by TRH on this promoter and that reported nTRE (Fig. 4) is dispensable for activation 
of the TRH-induced transcription.  
17.2 TRH-dependent activation vs. T3/TR-induced repression 
The in vitro data demonstrated by Ohba et al. (Ohba et al., 2011) correlate well with the in 
vivo findings (Fig. 7).  
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Fig. 7. Schematic representation of transcriptional regulation of the TSH┚ gene by TRH 
signaling and T3/TR. With support by Pit1, GATA2 maintains the basal transcription of the 
TSH┚ gene and mediates TRH/TRH-R1 signaling in hypothyroidism, while unliganded TR 
alone is not a transcriptional activator. Inhibition by T3/TR is dominant over activation by 
GATA2 even in the presence of TRH signaling. The release of T3/TR-induced repression (a) 
is more crucial for TSH┚ expression than TRH signaling (b) since the inhibition by T3/TR is 
dominant over the stimulation by TRH (c).  DNA binding of GATA2 with the TSH┚ 
promoter is facilitated by the TRH pathway (b). 
First, they showed that as long as T3 is at low concentrations or absent, expression of the 
TSH┚ gene is maintained by Pit1 and GATA2 without stimulation by TRH signaling (Fig. 
7(a)) (Gordon et al., 1997; Kashiwabara et al., 2009; Ohba et al., 2011). In agreement with this, 
the signaling and the number of TSH┚-positive cells in the pituitary of TRH-deficient mice 
were comparable with those of wild-type mice (Shibusawa et al., 2000). Second, given that 
unliganded TR is not a transcriptional activator, elevation of TSH┚ expression in 
hypothyroidism should depend on TRH signaling but not on unliganded TR (Fig. 7(b)). 
Nikrodhanond et al. (Nikrodhanond et al., 2006) compared TSH┚ expression in wild-type, 
TRH-, TR┚- and TRH/TR┚-double knockout mice and found that, in hypothyroidism, TSH 
expression predominantly depends on TRH signaling but not by unliganded TR┚. Since the 
authors regarded unliganded TR┚ as the stimulator for the TSH┚ gene, they mentioned that 
their findings were unexpected. However, their results are in agreement with the notion that 
unliganded TR is not the activator or mediator for the TSH┚ gene in the absence or presence 
of TRH signaling. Finally, our data suggested that, in TSH┚ transcription, the inhibitory 
effect by T3/TR is dominant over the TRH-induced stimulation (Fig. 7(c)) (Ohba et al., 2011). 
In accordance with this, an earlier study with human subjects indicated that continuous 
injection of TRH cannot release the inhibition of serum TSH in thyrotoxicosis (Chan et al., 
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1979). Taking advantage of the fact that the Pax8-null mouse is an excellent animal model 
for congenital hypothyroidism (Friedrichsen et al., 2004), Mittag et al. (Mittag et al., 2009) 
demonstrated that thyrotroph differentiation in Pax8/TRH-R double-knockout mice is 
comparable with that in the hypothyroidism of mice homologous for a Pax8-null allele. 
Their results support the notion that release of T3/TR-induced inhibition (Fig. 7(a) is more 
critical for TSH┚ expression than TRH signaling (Fig. 7(b)) because inhibition by T3/TR is 
dominant over stimulation by TRH (Fig. 7(c)).  
18. Mechanism of T3/TR interference with GATA2 transactivating function 
Negative regulation of the TSH┚ gene is expected to provide an excellent experimental 
model to study transcriptional regulation since this promoter is activated by TRH signaling 
and repressed by T3/TR (Fig. 6). An important next step would be to investigate how 
T3/TR interferes with the transactivation function of GATA2. As pointed out above, the 
involvement of RXRs, TR-related coactivator (p160) or co-repressors (NCoR, SMRT) has 
been controversial. We favor another possibility; that TR may regulate the function of 
GATA2-related cofactors in a T3-dependent manner.  
In pituitary-specific GATA2-null mice (Charles et al., 2006), the defect in TSH┚ expression 
was partial and GATA3 expression was increased. Thus, GATA3 may be able to 
compensate for the reduction in GATA2 expression and there may be functional 
redundancy between GATA2 and GATA3. Amino acid homology between the Zn-finger 
domains of GATA1, GATA2 and GATA3 is well conserved (Fig. 5B) and plays a pivotal 
role in DNA recognition as well as cofactor interaction (Bates et al., 2008; Shimizu and 
Yamamoto, 2005). Consistent with this, our in vitro results show that GATA1, GATA2 and 
GATA3 have the capacity to mediate cooperation with Pit1 (Kashiwabara et al., 2009), 
TRH signaling-induced transactivation (Ohba et al., 2011) and inhibition by T3/TR 
(Matsushita et al., 2007). All these properties were also observed in the deletion mutant of 
GATA2 that lacks an N-terminal domain (GATA2-ZC) or a C-terminal domain (GATA2-
NZ) (Fig. 5B). These findings suggest a critical role of the Zn-finger domain in GATA2 
(GATA2-Zf) in TSH┚ gene regulation. Besides CBP/p300, TR-associated protein (TRAP) 
220/MED1 and Friend of GATA (FOG) 1 or 2 are known to interact with this domain. Of 
course, there is the possibility that other unknown factors may play a critical role in 
negative regulation by T3/TR and that there is interplay among various histone 
modifications to achieve local control of TSH┚ gene transcription. Although the chromatin 
immunoprecipitation (ChIP) assay is expected to provide important information, the 
amount of endogenous GATA2 in T┙T1 cells may not be sufficient for this approach 
(Ohba et al., 2011). 
18.1 TRAP220/MED1 and Mediator complex 
TRAP220/MED1 is a constituent of the Mediator complex that directly regulates the 
function of RNA polymerase II (Pol II) (Fig. 6) (Chadick and Asturias, 2005). The following 
findings indicate the involvement of TRAP220/MED1 in transactivation by the GATAs (Fig. 
6). First, in vitro experiments show that TRAP220/MED1 interacts with GATA2-Zf (Gordon 
et al., 2006). Second, homozygous TRAP220/MED1-null mice are embryonic lethal due to an 
abnormality in cardiac function and its phenotype is reminiscent of that observed in mice 
deficient for the GATA family transcription factors (Crawford et al., 2002). Third, expression 
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of the TSH┚ gene is reduced in heterozygous TRAP220/MED-knockout mice (Ito et al., 
2000), suggesting that TRAP220/MED1 is required for expression of the TSH┚ gene, which 
is GATA2-dependent. Interestingly, TRAP220/MED1 possesses two LXXLL motives, which 
functions as an interface for interaction with the TR-LBD in a T3-dependent manner. Mutant 
TRAP220/MED1, which only has two LXXLL motives but lacks other transactivation 
domains, is reported to function as a dominant negative inhibitor against wild-type 
TRAP220/MED1 in T3-dependent positive regulation via TR-RXR heterodimers on the 
pTRE (Yuan and Gambee, 2000). Matsushita et al. (Matsushita et al., 2007) found that mutant 
MED1/TRAP220 also attenuates T3-induced inhibition of the TSH┚ gene. It was reported 
that mutant TRAP220/MED1 specifically interferes with the activity of wild-type 
TRAP220/MED1 but not other LXXLL-type co-activators including the p160 family and 
CBP/p300 (Acevedo and Kraus, 2003). Thus, there is the possibility that TR may regulate the 
activity of a complex containing GATA2 and TRAP220/MED1 in a T3-dependent fashion. 
Given that inhibition by T3/TR targets the final step of GATA2-induced transactivation, i.e. 
TRAP220/MED1-Pol II complex, repression might occur downstream of or at the same 
point as TRH-induced activation. This may account for the findings that inhibition by 
T3/TR is dominant over TRH-induced activation of the TSH┚ gene (Mittag et al., 2009; Ohba 
et al., 2011). In vivo experiments with mouse embryonic fibroblasts showed that the 
requirement of TRAP220/MED1 may be specific to TR, but not to RAR or VDR (Ito et al., 
2000). Intriguingly, the binding of different activators triggers a specific conformational 
change in the Mediator complex, which may have a critical role in the regulation of Pol II 
(Chadick and Asturias, 2005).  
18.2 FOG2 and chromatin-remodeling factors 
The co-repressor, friend of GATA (FOG) 1 or 2 (Cantor and Orkin, 2005) may be involved in 
T3/TR-induced negative regulation via GATA2. FOG1 and FOG2 interact with the N-
terminal Zn finger of the GATAs and recruit chromatin-remodeling factors (Fig. 6) (Hong et 
al., 2005; Roche et al., 2008; Rodriguez et al., 2005). In addition, FOG2 is expressed in non-
hematopoietic tissues and interacts with TR┚ (Rouf et al., 2008) and other NHRs (Clabby et 
al., 2003; Huggins et al., 2001). Matsushita et al. (Matsushita et al., 2007) generated a mutant 
GATA2 (C295A) which is predicted to have impaired interaction with the FOGs. Although 
the basal transcriptional activity of this mutant was also reduced (by approximately half) 
compared with wild-type GATA2, inhibition by T3/TR (fold repression) was significantly 
relieved in mutant GATA2.  
19. Molecular mechanism of SITSH in RTH 
As described above, patients with RTH exhibit SITSH (Refetoff et al., 1993). The mutant TR┚ 
found in RTH patients is supposed to interact with GATA2 because it has an intact DBD, 
which is the interface for the Zn-finger domain of GATA2. Nakano et al. (Nakano et al., 
2004) tested whether mutant TR┚2s identified in RTH patients exhibit a dominant negative 
effect on the negative regulation of the TSH┚ gene using CV1 cells cotransfected with Pit1, 
GATA2 and wild-type TR┚2. As predicted, mutant TR┚2s blunted the T3-induced inhibition 
of the TSH┚ gene by wild-type TR┚2. Although these findings are likely to be the result of 
dominant-negative interference of wild-type TR┚ function by mutant TR┚, further studies 
are required with regard to its molecular mechanism. Following questions also remain. First, 
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in patients with non-TR RTH (see above), no genetic abnormalities in the TR┚ or TR┙ genes 
have been identified. Although linkage analysis of these patients showed no relation with 
NCoR, SMRT, SRC-1 or RXR┛ (Reutrakul et al., 2000), an understanding of the 
transcriptional control mechanisms underlying non-TR RTH may provide an insight into the 
molecular basis of negative regulation of the TSH┚ gene. Second, RTH is clinically classified 
as a generalized resistance to thyroid hormone (GRTH) and resistance of the pituitary to 
thyroid hormone (PRTH) (Refetoff et al., 1993). Patients with PRTH possess mutations 
similar or identical to those found in GRTH; however, PRTH patients display greater 
resistance to thyroid hormone in thyrotrophs compared to peripheral tissues, resulting in 
thyrotoxicosis. Currently, the mechanism of pituitary-dominant resistance in PRTH is 
unknown (Nakano et al., 2004).  
20. Mechanism of logarithmic alterations in serum TSH by linear changes of 
T3/T4  
TSH synthesis in the pituitary is dramatically altered by subtle changes in serum T3 and T4. 
Indeed, linear changes in the concentration of serum T4 and T3 correspond to logarithmic 
changes in serum TSH (Fekete and Lechan, 2007; Fisher et al., 2000; Kakucska et al., 1992). 
Such a sensitive alteration of TSH┚ expression may be necessary for thyroid hormone 
homeostasis (Fig. 1A) because TSH signaling is thought to be one of the most critical 
determinants of T3 and T4 synthesis in the thyroid gland. In other words, serum TSH level 
has been regarded as most sensitive clinical marker for thyroid gland function. Indeed, 
SITSH is an important indicator for RTH.   
With regard to the molecular mechanism of logarithmic changes in serum TSH, there are the 
following possibilities. First, T3/TR negatively regulates not only TSH┚ and ┙GSU but also the 
prepro-TRH gene (Fig. 1A). Thus, the dual inhibitory mechanism at the hypothalamus and the 
pituitary may be important for the non-linear change of serum TSH level. Second, Pit1 
expression may be negatively regulated by T3 (Sanchez-Pacheco et al., 1995). Because this was 
found in a somatotroph cell line, GH3 (Ooi et al., 2004), which lacks endogenous GATA2 
(Gordon et al., 1997), an unknown pituitary factor may be involved in this inhibition. Third, 
expression of GATA2 in thyrotrophs may also be negatively regulated by T3. It was reported 
that there are two promoters in the GATA2 gene, and that the distal one contains a GATA-RE 
(Kobayashi-Osaki et al., 2005). Therefore, there may be a positive feedback mechanism in the 
expression of GATA2 and this mechanism is thought to be crucial in the differentiation of 
hematopoietic cell lineages. There is the possibility that, in thyrotrophs, T3/TR may interfere 
with the transactivation function of GATA2 not only on the TSH┚ promoter but also on the 
GATA2 promoter. In addition, GATA2 protein may be quickly degraded by the ubiquitin 
system (its half life is approximately 30 min) (Minegishi et al., 2005). This may also contribute 
the drastic regulation of serum TSH level. Finally, there is the possibility that T3-induced 
inhibition of prepro-TRH expression in the hypothalamus may also be logarithmic (Fekete and 
Lechan, 2007; Kakucska et al., 1992). Although an nTRE was postulated in the prepro-TRH 
promoter (Hollenberg et al., 1995), the molecular mechanism of logarithmic inhibition of 
prepro-TRH expression by T3 is unknown.   
The diagnoses of both subclinical hypo- and subclinical hyper-thyroidism also depend on 
the sensitive change in serum TSH level.  Although serum free T3 and T4 levels are within 
normal range, subclinical hypo- or hyperthyroidism influence lipid metabolism (Walsh et 
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al., 2005b) and cardiovascular function (Walsh et al., 2005a).  In their pathogeneses, there 
may be the abnormality in the transcription of the gene which is negatively regulated by T3 
as robustly as the TSH gene.   
21. Other genes negatively regulated by T3/TR 
Microarray analyses revealed that approximately 30 to 50% of T3-target genes are negatively 
regulated (Feng et al., 2000; Weitzel, 2008). Therefore, elucidation of negative regulation by 
T3 is thought to be the next frontier.  
21.1 Reported nTREs in other T3-negatively regulated genes 
In addition to the TSH┚ gene, negative regulation by T3/TR has been reported in the genes for 
┙GSU (Chatterjee et al., 1989; Pennathur et al., 1993), MHC┚ (Edwards et al., 1994; Wright et al., 
1999), prepro-TRH (Hollenberg et al., 1995; Satoh et al., 1996), RSV-LTR (Saatcioglu et al., 1993), 
rat Na, K-ATPase ┙3 subunit (Chin et al., 1998), Nm23-H1 (Lin et al., 2000), phospholamban 
(PBL) (Belakavadi et al., 2010), rat CD44 (Kim et al., 2005), superoxide dismutase-1 (Santos et al., 
2006), deiodinase type 2 (Dio2) (Christoffolete et al., 2006) and ┚-amyloid precursor protein 
(Villa et al., 2004). In some of these genes, the existence of single half-sites homologous to the 
TSH┚ nTRE have also been postulated (Chatterjee et al., 1989; Chin et al., 1998; Edwards et al., 
1994; Hollenberg et al., 1995; Kim et al., 2005; Lin et al., 2000; Pennathur et al., 1993; Saatcioglu et 
al., 1993; Santos et al., 2006; Villa et al., 2004; Wright et al., 1999). However, there are few 
experimental studies that show the molecular mechanism by which these putative nTREs 
reverse the function of T3/TR from transcriptional activator to repressor. In TR┚- and/or TR┙1-
deficient mice, the expression of ┙GSU (Forrest et al., 1996; Gothe et al., 1999) in the pituitary, 
prepro-TRH in the hypothalamus (Abel et al., 2001; Dupre et al., 2004) and MHC┚ in the heart 
(Mansen et al., 2001) are maintained, suggesting that, as in the case of the TSH┚ gene, the basal 
activities of these genes are also maintained by a transcriptional activator other than unliganded 
TR. Thus, existence of nTREs in these genes should also be reconsidered.   
21.2 Possible involvement of the tethering mechanism 
If T3-dependent inhibition of these genes occurs via a tethering mechanism between a DNA-
binding transcription factor and T3/TR, identification of such a transcription factor may 
provide an insight into the molecular mechanism of T3-induced inhibition. As discussed 
above, a functional GATA-RE in the ┙GSU promoter may be the target of suppression by 
T3/TR. GATA-REs are also predicted in the promoters of Dio2 (Dentice et al., 2003), MHC┚ 
(Hasegawa et al., 1997; Morimoto et al., 1999) and PBL (Belakavadi et al., 2010). Dio activity 
in the thyrotrophs regulates the intracellular concentration of T3, which is the determinant 
of negative regulation of the TSH┚ gene (Escobar-Morreale et al., 1996). Although Dio1 and 
Dio2 are expressed in thyrotrophs, the inhibitory effect on TSH by T3 was relieved in mice 
deficient for Dio2 but not Dio1 (St Germain et al., 2005), indicating the crucial role of Dio2 in 
the regulation of T3 concentration in the thyrotroph. Further studies may clarify the role of 
the predicted GATA-RE in the Dio2 promoter (Dentice et al., 2003) and the complexity of the 
T3 sensing mechanism in regulation of the TSH┚ gene (Christoffolete et al., 2006). Although 
it was previously reported that the GATA-RE in the MHC┚ gene plays a role in its 
transcriptional activity (Hasegawa et al., 1997; Morimoto et al., 1999), other investigators 
suggested that it may not be functional (Vyas et al., 1999). Another study of the MHC┚ 
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promoter using rat neonatal cardiomyocytes suggests that the M-CAT site in this promoter 
is critical for its expression (Flink et al., 1992). M-CAT is the recognition site for the TEF 
family of transcription factors (Yoshida, 2008). TEF family transcription factors are the major 
target of ┙1 adrenaline signaling (Chen et al., 2004), which is known to mimic the cardiac 
phenotype seen in heart failure (Yoshida, 2008). Consistently, overexpression of TEF-1 in 
vivo exhibits a phenotype similar to that of chronic heart failure (Tsika et al., 2010). Our 
preliminary data suggests that T3/TR inhibits TEF-dependent transactivation of the MHC┚ 
gene.  
22. Negative regulation by liganded NHRs other than TR  
A tethering mechanism has been reported in genes that are negatively regulated by liganded 
NHRs other than T3/TR. For example, the proopiomelanocortin (POMC) gene is activated 
by a transcription factor, Nur77, which is also the mediator of corticotropin-releasing 
hormone (CRH) signaling (Maira et al., 2003). Liganded GR interferes with this activity via a 
tethering mechanism (Martens et al., 2005). Moreover, a recent report suggested the 
involvement of chromatin remodeling factors in inhibition of the POMC gene by liganded 
GR (Bilodeau et al., 2006). Expression of parathyroid hormone (PTH) is inhibited by 
liganded VDR. PTH expression is maintained in the mice deficient for the VDR gene (Kim et 
al., 2007), suggesting that unliganded VDR is not the transcriptional activator for the PTH 
gene.  A DNA-binding transcription factor, VDR interacting repressor (VDIR), binds with 
the promoter region of the PTH gene and activates its transcription (Kim et al., 2007). It was 
reported that VDR associates with VDIR (Kim et al., 2007; Murayama et al., 2004), resulting 
in VD3-dependent inhibition. A tethering mechanism between liganded VDR and VDIR also 
plays a role in negative regulation of human 1┙(OH)ase (CYP27B1) expression by VD3 
(Murayama et al., 2004). In this scenario, a chromatin remodeling factor complex (Kitagawa 
et al., 2003), and a DNA methylation-related proteins (Kim et al., 2009) may play crucial 
roles.  
23. Conclusion 
Negative feedback is the key component in homeostasis of hormones. A typical example is 
the inhibition of TSH synthesis by T3/TR. Although serum TSH levels are increased in 
hypothyroidism, observations in TR-knockout mice (Forrest et al., 1996; Gothe et al., 1999), 
human subjects with a deletion of the TR┚ gene (Takeda et al., 1992) and in vitro experiments 
(Nakano et al., 2004) provide evidence that unliganded TR is not a transcriptional activator 
(Fig. 7). Moreover, deletion analysis of the TSH┚ gene with co-expression of GATA2 and 
Pit1 revealed that a putative nTRE (Fig. 4) is dispensable for inhibition by T3/TR 
(Matsushita et al., 2007). Study of the TSH┚ gene suggests the importance of a transcription 
factor that maintains the basal transcriptional activity of the promoter before ligand addition 
(Fig. 7). Identification of the factor required for the basal promoter activity may also be 
important and the first step in the analysis of other promoters that are repressed by T3/TR 
or other liganded NHRs.  The factor may interact with NHRs.  Once such a transcription 
factor is identified, it will be possible to study negative regulation using cells that express 
the factor and to carry out reporter analysis with co-transfection of its expression plasmid. 
For example, it will be possible to compare the mechanisms of positive and negative 
regulation using same cell line, for instance CV1 (Nakano et al., 2004).  Information of the 
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factor required for the basal promoter activity would be helpful to avoid artificial negative 
regulation mediated by plasmid backbones (for example a pUC/pBR322-derived AP-1 site 
or firefly luciferase cDNA).  We are only just beginning to unravel some of complexities 
involved in negative regulation by liganded NHR including T3/TR.   
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